Boston Scientific Corporation(BSX: Quote), a maker of medical devices, Friday said it launched a clinical trial, OPTIMISE, to find out if occipital nerve stimulation or ONS using the Precision System can safely and effectively treat chronic migraine when used in conjunction with anti-migraine medications. The multi-center, randomized, placebo-controlled study is expected to be used to support various regulatory approvals of this novel therapy for chronic migraine.
With ONS, a small programmable implanted device sends electrical impulses to the greater occipital nerve, which runs from the top of the spinal cord to the base of the scalp. The Precision System for chronic migraine is investigational and is currently available as an approved treatment in the U.S., Canada, Europe and Australia as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome and intractable low back pain and leg pain.
"We believe that the Boston Scientific neurostimulation therapy for migraine has enormous potential to help migraine sufferers worldwide..." said Maulik Nanavaty, president, Neuromodulation, Boston Scientific.
Click here to receive FREE breaking news email alerts for Boston Scientific Corp and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org